Legend Biotech reports first quarter of company-wide profitability with $63M adjusted net income

Legend Biotech / Johnson & Johnson

Legend Biotech achieved company-wide IFRS and adjusted profitability in Q2 2026 with $63 million in adjusted net income, driven by CARVYKTI sales growth. The company ended the quarter with $965 million in cash and no long-term debt, and expects to remain adjusted-profitable through H2 2026.

• Q2 2026: First quarter of company-wide profitability
• $63 million adjusted net income in Q2 2026
• $965 million cash position at quarter-end with no long-term debt
• Company expected to remain adjusted-profitable through second half of 2026